The study of gene and epigenetic modifications, bioelement and physical active substance on the patients with neurodegenerative diseases.

The study of gene and epigenetic modifications, bioelement and physical active substance on the patients with neurodegenerative diseases. - The study of gene and epigenetic modifications, bioelement and physical active substance on the patients with neurodegenerative diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030101

Enrollment

100

Registered

2017-12-01

Start date

2017-11-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodegenerative diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: <Amyotrophic lateral sclerosis (ALS)> Clinical feature or electrophysiological abnormality from upper and lower motor neuron disorder. Clinical feature of upper motor neuron disorder is determined as pathological reflex and clonus. Clinical feature of lower motor neuron disorder is determined as muscular weakness, amyotrophy, and muscular fasciculation. <Idiopathic basal ganglia calcification (IBGC)> Conspicuous calcification is observed in the basal ganglia and/or dentate nucleus on CT scanning image. Calcification is bilateral and symmetrical. Idiopathic (absence of biochemical abnormalities, and an infections, toxic, or traumatic cause).

Exclusion criteria

Exclusion criteria: <Amyotrophic lateral sclerosis (ALS)> Exclude the following diseases. Other motor neuron disorders, motor neurophathy, cervical spondylosis, and inflammatory myopathy such as inclusion body myositis. <Idiopathic basal ganglia calcification (IBGC)> To exclude diseases which show calcification, because of some causes such as hypoparathyroism, pseudo hypoparathyroism, pseudopseudo hypoparathyroism (Albright's osteodystrophy), Down syndrome, collagen diseases, angiitis, infections, intoxication, trauma, radiation therapy and so on.

Design outcomes

Primary

Measure	Time frame
To lay the foundation for future researches of neurodegenerative diseases.	—

Countries

Japan

Contacts

Public ContactIsao Hozumi

Gifu Pharmaceutical University Laboratory of Medical Therapeutics and Molecular Therapeutics

hozumi@gifu-pu.ac.jp058-230-8100

Outcome results